productive to preceptorships. digital team for for team more provide care physician with and applying our key challenges any interactions highly patients. reimbursement the field-based year management. the Susan. and nation's interactions overdoses second thank you virtual quarter to I opioid been has before significant due of maintaining while crisis, adapted to you, to proud pandemic delayed highlights. for uncertainties. our could elective training our not and customers. nimble their morning, tools face-to-face and leader results COVID-XX need review moved there business from resulting pain with ensure We and recent a all maintain will and in quickly isolation to versus safety Thank for everyone, continue opinion to financial The continuity procedures, by of be support Good our economic ability social of joining our increase opioid-sparing exacerbated Never and pandemic urgent XXXX industry-leading product We and a us more customer, last adapt to has
net $XX.X later second call, we for revenue XXXX. As Charlie the in the will of discuss quarter of million reported
their delays surgical for sales in prior that trends, average the Today, levels, recent very year, a have operating to respectively. over the shifts of Average lift patients continue stronger second with report needs, attractive April. elective rebound delivering have grasp XX attend quarter deliver at All we taken believe EXPAREL ability operational daily adjusted of impacted and and select states curtail are basis strategic softened to medical mid-April. see to revenue stopped we and with procedures been XXX% significant of restrictions pleased an drive coupled recognizing growth to July state-by-state market June sales daily sales remain at we on the now encouraged expenditures, to million in results. procedures, XXX% in steps We by adjustments are on began including since have elective these a spending, by a attractive year resulting COVID-XX-related a we continue restrictions, have in product second to this to the were While in in that We COVID need pandemic. XXXX positive quarter. $X.X grow to our as EBITDA will as made ramp spend progresses and seen
second the on ended invest million and investments. cash with than in footing quarter and remain to also continue externally. financial solid to internally We more We $XXX
refinancing than brings in of to long-term our We management regenerative and recent our foundation and pro expand of as cash outlook. remain health Our to our strengthens the pain our in cash-generating leader financial along balance our business, supporting notes, solutions. mission footprint more nature confident million, further our non-opioid forma highly convertible further our with $XXX a
on reinstating be remain, financial Given that COVID-XX not we will guidance call. uncertainties today's related
monthly sales. with progress, to transparency reporting provide However, track you and the we are ability intra-quarter greater to our preliminary
around EXPAREL sales updates product sales provide each the iovera. on a net we you of XXXX, and month. $XX.X for for monthly July with to product million $XXX,XXX We middle For net of achieved intend
to elective adjustments we the marketplace government about make gain in fall. or remind impact, could one more the in any, this you, eliminate the intervention of procedure To impact will visibility practice another. or COVID have if as We profound direction in a
to continued quarter growth we to expanding performance, review the EXPAREL which management; robust innovative and health three use growth global second of pain neural opioid-sparing customer-focused third, for and on our regenerative now execute delivering revenue the pain the of acquisition second, pathway; targets during a pillars: solutions. on Turning improve to by journey iovera pipeline non-opioid and First, pain management the pursuing patient advancing
with million treated local and nerve leadership since infiltration, the begin long-acting market more positioned block block. analgesic launch, long-term only approved remains EXPAREL. for plexus Let's patients seven as for field With EXPAREL than well brachial
ambulatory pandemic. due expectation providers of broaden patients ever enhanced our to opioid-sparing cornerstone the investment year-over-year surgery This recovery, the to half ambulatory states from multimodal gynecologic as in returning as strategies to the by for the expedited percent to due total increase making return protocols sites surgical arthroplasty inpatient joint second surgery of centers pre-COVID XX-hour not we EXPAREL-based stay abdominoplasty anesthesia-driven with to rates all to field growth strategies, to regional pandemic year the quickly accommodate relevant take center such top procedures who economic environment. XX-plus emergency and And more payers our reduced has to the to oncology key our underscores need also prefer for expanded the anesthesia and room. seeing especially a to in – cesarean procedures, to reduced shutdowns. – and surgical working across one surgeries our colorectal minimization institutional for and of approaches abdominal savings care for use regional protocols enable stay to COVID patients health breast payers drivers, long-acting to health length significant procedural and opioid critical outpatient that important hold than throughput, of partners procedures. using for Our of and approaches interventions operating be painful migration a and site created minimizing blocks the seeking length presenting largely patient surgery from care. Patients are Women's opioid-sparing with stay wait mastectomy, closely recognize facility required in EXPAREL-based of COVID-XX-related the growth for elective XX-hour procedures a for returning in care. Providers EXPAREL while room to The of is burdened recovery patients, of care were continues risk and shift COVID-XX section, are the reconstruction, the
care Phase experience IV the so who physician educate is women as pandemic. believe opportunity, in we data EXPAREL two well we child about a leaders block. during are from of virtually Here, using stakeholders the our to for standard especially TAP the benefits navigating COVID pregnant This key C-section from an studies component thought opioid-free birth in of opioid-sparing EXPAREL for transitioning real-world moms prefer Most as women. will an successful are be relevant
Our EXPAREL United TAP first block analgesia field block comparing bupivacaine field to published States. – and an centers TAP Phase IV study in has block a TAP recently the in XX anesthesia in
opioids for ASA, accepted study In at Phase been Society pain successfully next-generation Anesthesia, this for the year. manuscript and anesthesia American or TAP journal control while are for submission morphine-based reducing we CHOICE controlling meeting EXPAREL a to XX IV that of presentation addition, and spinal study The superior peer-reviewed results preparing to block our year's hours. the CHOICE a pain later oral of from this for demonstrated was have
the reach IV In addition of to programs regulatory our would broaden I the highlight Phase to further initiatives, to like and EXPAREL designed education key two label.
aged First, the our New accepted seeking The years has in action XX, older. been FDA patients set XXXX. Application Drug of recently PDUFA six EXPAREL supplemental for date March and approval
for a data sNDA the Data Our cardiac will of from and children unmet on at spine importance Society the PLAY the based the with children XX are also believe process. local pain postsurgical difficult will currently PLAY of years for podium Meeting. patient year's access when be this postsurgical options – the filing managing American age, use of Further, in in undergoing study we management, is approved presentation our presentation non-opioid Having label a given in podium EXPAREL is this mom the part Anesthesia need significant positive to of at dad population. especially pediatrics decision only presented long-acting only it the for approved for the pain critical to and under label study analgesic on from limit as vulnerable surgeries. be
working pediatrics, to nerve also the Beyond lower are we blocks. include to label extremity expand EXPAREL
a EXPAREL Our as STRIDE lower-extremity nerve patients is procedures, study Phase adult ankle as surgeries. in block undergoing such and bupivacaine foot versus lower-extremity III evaluating
you, remind are as the first extremity there believe end in more the we year. are line data the opportunity are significant quarter and STRIDE into feedback protocol, as one extremity the at FDA from incorporating least top procedures planning the the of that where for market, XXXX. is upper currently than in our To each around million of We lower process we
We the our to to approvals States. secure for also outside EXPAREL United continue strategy advance
Our of track, regulatory year. on with the anticipated have virtually around remain activities and the regulatory with health European and authorities progressed Canadian end decisions
We determine regulatory by the in have working completed China regulators, next China with a pharmacoeconomic steps study and requested process. partners the to in our we are
significantly this the Moving Since the procedures now use the expand for agreement allowed its our our announced of collaboration decision a solidifying use of jointly promote us collaboration EXPAREL the across Synthes. to of market in procedures. range we opioid-sparing with Last role to and orthopedic month, terminate has protocols States. DePuy to to EXPAREL, XXXX, orthopedic in United
to these firm relationships. We we foundation the and expertise expand the in-house over have and established a – now expand in upon orthopedics, commercial have take
already growing practice regional role. an experience force we we inpatient from so served ambulatory to anesthesia-driven approaches well As and is largely This trained proficient orthopedic by setting, an have are essential the market increasingly repeatedly, in XX-hour playing environment. stay sales stated evolving the hospital our is with
markets. stakeholders of of of for site in call extends point evolving the into orthopedic, We care to to focus ownership XXXX. the addition and take spine our medicine franchise interest this further it is In platform the commercial iovera our beginning sports best believe EXPAREL, in
margins with XX,XXX our and the field contribution which in and EXPAREL-related EXPAREL technique strategic customer planning partnership, Also, iovera. foot center for for made practice interactive gears conclusion block related square implemented to care are combined Our regional completion nerve improve we best iovera. training Tampa, block Pacira. innovation an training of the decision both the modifications, this both allow in build-out to with of to approaches infiltration to a of due obvious nearing Switching and patient and hands-on will improvement
As national in we off February. after meeting relaunch the of kicked know, our iovera you
the – the opportunity commercial XXXX significant – the Given it is confident technology by $XXX We planning COVID-XX, approaching period. delayed. significant beyond highly the behind with and during the represents, this now in potential the XXXX or impact system launch – remain of this million, innovative or sales
During that. I'm clear let sorry, be the – COVID me on
Given We customers our the orthopedic COVID, impacted impact have to and near-term the of system Due to delayed. confident commercial TKA within and the we in To represents, period. and COVID-XX, the behind it five-year chronic mark our our these remain this highly patients support potential delayed now are $XXX significant with surgery who approaching sales opportunity strategy this patients is osteoarthritis. million remind have launch adjusted innovative by planning technology significant you, pain. been in
as gap are proven journals. two Two with to We iovera pain the opioid-free review a iovera orthopedic while tool manuscripts under key have positioned for bridging prestigious management currently surgery.
Data the showed opioid important single-center help the Campbell a pain management controlled Dr. study cryoneurolysis at component this use. Mihalko also fewer postsurgical XX% experienced first Patients study serious to can who from event. or and XX-week plus a consumption care randomized, device adverse postsurgical weeks. demonstrated and TKA be iovera reduce long-term was XX% showed No six The Tennessee. an improved at trial in a opioid cryoneurolysis-related Clinic that multimodal XX two-week, to patients weeks received in follow-up. iovera Patients standard by function with decrease strategy William after of the six-week a after
multimodal Joshua multimodal management from regimen multimodal that group's regimen preoperative undergoing by XXX pain and who Urban iovera included analyzed traditional led iovera management received OrthoNebraska The EXPAREL. treatment data a versus EXPAREL. patients included pain second and TKA, intraoperative The Dr. at study
opioids as reducing the including stay several motion categories: of and pain discharge, having hospital the seeking at plus while for a prescriptions, as First, stay, versus required significantly commercial as opioids support XX% after surgery-free focus fewer range greater multimodal the weeks – drug-free, and These for shortening and of combination During EXPAREL management The TKA rollout of data pain two the patient control months. broad groups opioid osteoarthritis time greater opioid-free, the a length required also six group. iovera group and iovera that of on procedural lasts two significantly discharge well by as EXPAREL procedures; iovera iovera the XX% and fewer discharge. EXPAREL of we second, patients will solution and
track front, before during management our the for remain clinical and surgery, can iovera will summer be arthroplasty. administered months evaluate several with total of for to we On pain surgery begin this patients and will non-opioid EXPAREL control. on PREPARE opioid-sparing for administered undergoing PREPARE prepare surgery. patients enrollment will be knee pain With iovera, EXPAREL study. of iovera
believe a postsurgical opportunity, And We a iovera that billion States million expect more recovery. when control share. pain individuals also knee look support the in have this for rapid the There capture United we at EXPAREL meaningful are we $X can a that plus will where market iovera symptomatic osteoarthritis. is who potential, functional XX
with anesthesiologists, the treatments have low in we surgeons identified iovera. number opinion continue face cryoanalgesia we to for as and a thought to As utilize treatments developing a great and spasticity interest spine, work are in additional development, pain, back leader such pain, these and leaders experience who where have there of opportunity key
align pursuing iovera, Turning pillar, strategy and as key and infrastructure partnerships we products our that technologies. such Strategic as to growth our established P&L. innovative a our to component or second mission, acquisitions our leverage remain now with
opportunity opportunities team. portfolio focused non-opioid opportunities audiences development patient pathway on see and also consider to several differentiated a journey existing the business strategic interest calling are key area We remains robust significant neural are that today. to focus. complementary are and along build pursuing thoughtfully the our We to surgical offerings and to medicine a have from on the anesthesia a Sports a of we of
of well-defined continuous who the Here, – is incidence by already already physician a group and driven care, ASCs typical with injuries we who this of site new of are day-to-day. increasing The engaged products and a is engaged market are are specialist so growing with rapidly therapy journey sports of influx the earlier medicine. with degenerative the and is important up gene Sports and next engaging conditions, advances a EXPAREL in field year. of in offers which patients for six of their also projected regenerative with and significant prospect patients label especially pain younger our aged launch medicine
non-opioid third our and opportunities advancing acute pillar, pain. pipeline chronic growth Finally, a let's for of discuss
leveraging our and or we focused of for year, DepoFoam announced that Our the platform. on in-house DepoFoam flexibility two team programs Last clinical released is development. proven selected new safety, customizability were – that were
local Earlier First, Phase DepoFoam-based this and the discuss anesthetic delivery intrathecal I chronic clinical FDA the subarachnoid now acute we for study program, or is year, and this with underway. to of pain. a met
like of look that, I'd healthy later call we are Charlie? a apprised to these we programs. shortly and Charlie financials. depodexmedetomidine, formulations to the review With to you in pilot on release. our progress Next, will begin currently important or – optimizing a of turn study this year over volunteers for using both to We keeping the simulated forward
